RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Austen BioInnovation Institute, FDA to Partner on Medical Device Regulation

Austen BioInnovation Institute, FDA to Partner on Medical Device Regulation

Posted 21 December 2011

The Austen BioInnovation Institute in Akron (ABIA) is collaborating with the US Food and Drug Administration to share its expertise in the use of biomaterials and polymers in medical devices. The goal of the partnership is to help the US Food and Drug Administration (FDA) more effectively regulate the safety and performance of the materials when they're used in the manufacture of medical devices, according to a statement from the ABIA.  The FDA establishes these sorts of external partnerships to leverage the expertise of academic and research institutions to help the agency stay up-to-date with the latest scientific and medical advances.  The ABIA is also engaging with the federal government on the group's "value-driven engineering" initiative. (Med City News)

 

© 2022 Regulatory Affairs Professionals Society.